• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VENETOCLAX Drug Record

  • Summary
  • Interactions
  • Claims
  • VENETOCLAX chembl:CHEMBL3137309 ApprovedAntineoplastic

    Alternate Names:

    VENETOCLAX
    RG-7601
    ABT-199
    RG7601
    VENCLEXTA
    GDC-0199
    4-{4-[(4'-CHLORO-5,5-DIMETHYL[3,4,5,6-TETRAHYDRO[1,1'-BIPHENYL]]-2-YL)METHYL]PIPERAZIN-1-YL}-N-(3-NITRO-4-{[(OXAN-4-YL)METHYL]AMINO}BENZENE-1-SULFONYL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE
    rxcui:1747556
    pubchem.compound:49846579
    chembl:CHEMBL3137309
    drugbank:11581
    chemidplus:1257044-40-8

    Drug Info:

    FDA Approval Chronic lymphocytic leukemia (with 17p deletion)
    Drug Class Small molecule inhibitor
    (5 More Sources)

    Publications:

    Konopleva et al., 2016, Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia., Cancer Discov
    Huemer F et al., 2019, Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM., Eur J Haematol
    Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
    Davids et al., 2013, ABT-199: taking dead aim at BCL-2., Cancer Cell
    Souers et al., 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets., Nat. Med.
    Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica
    Birkinshaw RW et al., 2019, Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations., Nat Commun
    Blombery P et al., 2020, Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax., Blood
    Lucas F et al., 2020, Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations., Blood
    Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov
    Blombery P et al., 2019, Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma., Br J Haematol
    King AC et al., 2017, Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies., Ann Pharmacother
  • VENETOCLAX   IGH

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • VENETOCLAX   IDH2

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type predicted – sensitive
    Approval Status Phase II

    PMIDs:
    27520294 30725494


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • VENETOCLAX   BCL2

    Interaction Score: 1.7

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor
    Direct Interaction yes

    PMIDs:
    23410971 23291630 31004028 31160589 31951646 32232486 30514704 31234236 28056525


    Sources:
    MyCancerGenome ChemblInteractions CIViC TTD

  • VENETOCLAX   NPM1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • VENETOCLAX   FLT3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • VENETOCLAX   PTEN

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BEZ235 + Venetoclax
    Indication/Tumor Type breast cancer
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • VENETOCLAX   BRAF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • VENETOCLAX   IDH1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type predicted – sensitive
    Approval Status Phase II

    PMIDs:
    27520294 30725494


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • VENETOCLAX   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Venetoclax + VX-11e
    Indication/Tumor Type colorectal cancer
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • VENETOCLAX   PIK3CA

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BEZ235 + Venetoclax
    Indication/Tumor Type breast cancer
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • VENETOCLAX   TP53

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • MyCancerGenome: VENETOCLAX

    • Version: 20-Jun-2017

    Alternate Names:
    VENCLEXTA Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Chronic lymphocytic leukemia (with 17p deletion)

    Publications:

  • JAX-CKB: Venetoclax

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
    Konopleva et al., 2016, Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia., Cancer Discov

  • CIViC: VENETOCLAX

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Huemer F et al., 2019, Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM., Eur J Haematol
    Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica
    Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov

  • TTD: GDC-0199

    • Version: 2020.06.01

    Alternate Names:
    D00PBX TTD Drug ID

    Drug Info:

    Publications:

  • TTD: RG7601

    • Version: 2020.06.01

    Alternate Names:
    D0I6OI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3137309

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: venetoclax

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Venetoclax

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3137309

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21